Telomere Lengths in POAG Trabecular Meshwork Cells
About the Research Project
Program
Award Type
Standard
Award Amount
$25,000
Active Dates
April 01, 2000 - March 31, 2001
Grant ID
G2000020
Summary
The ends of chromosomes, called telomeres, shorten each time that most cells in the body divide. When telomeres become too short, cells can no longer divide and eventually die. Dr. O’Brien has uncovered evidence that trabecular meshwork cells from eyes with primary open angle glaucoma (POAG) undergo fewer cell divisions in culture than normal TM cells. He is exploring the possibility that these cells have shorter telomeres and therefore a decreased proliferative capacity. If telomere length is found to be decreased in POAG TM cultures, Dr. O’Brien will attempt to introduce the gene required for telomere maintenance (telomerase) to determine if he can restore proliferative capacity. If the TM cells can be preserved in this way, this research could lead to new treatments for glaucoma patients.
Related Grants
National Glaucoma Research
Developing New Drugs for Glaucoma
Active Dates
January 01, 2026 - December 31, 2027
Principal Investigator
Pete Williams, PhD
Current Organization
Karolinska Institutet
Developing New Drugs for Glaucoma
Active Dates
January 01, 2026 - December 31, 2027
Principal Investigator
Pete Williams, PhD
Current Organization
Karolinska Institutet
National Glaucoma Research
Assessment of Vascular Resistance in Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Brad Fortune, OD, PhD
Current Organization
Legacy Devers Eye Institute
Assessment of Vascular Resistance in Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Brad Fortune, OD, PhD
Current Organization
Legacy Devers Eye Institute
National Glaucoma Research
Interleukin-10 As a Neuroprotective Factor in Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Tatjana Jakobs, MD
Current Organization
The Schepens Eye Research Institute, Mass. Eye and Ear
Interleukin-10 As a Neuroprotective Factor in Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Tatjana Jakobs, MD
Current Organization
The Schepens Eye Research Institute, Mass. Eye and Ear